Simonetta Kerim
- Hematology top 5%
- Acute Myeloid Leukemia Research 11
- Chronic Myeloid Leukemia Treatments 8
- Genetics top 10%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 8
- Chronic Lymphocytic Leukemia Research 6
- Otorhinolaryngology top 10%
-
- Viral-associated cancers and disorders 4
-
- Lymphoma Diagnosis and Treatment 5
-
- Eosinophilic Disorders and Syndromes 5
-
- Glycosylation and Glycoproteins Research 3
In The Last Decade
Simonetta Kerim
34 papers receiving 501 citations
Peers
Comparison fields: 5 of 51
- Hematology 232
- Genetics 121
- Otorhinolaryngology 31
- Oncology 137
- Pathology and Forensic Medicine 77
Countries citing papers authored by Simonetta Kerim
This map shows the geographic impact of Simonetta Kerim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simonetta Kerim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simonetta Kerim more than expected).
Fields of papers citing papers by Simonetta Kerim
This network shows the impact of papers produced by Simonetta Kerim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simonetta Kerim. The network helps show where Simonetta Kerim may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Simonetta Kerim, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 2 | |
| 2 | 2015 | 1 | |
| 3 | 2010 | 33 | |
| 4 | 2009 | 16 | |
| 5 | 2006 | 21 | |
| 6 | 2006 | 40 | |
| 7 | 2004 | 18 | |
| 8 | 1999 | 12 | |
| 9 | 1998 | 19 | |
| 10 | 1994 | 41 | |
| 11 | 1994 | 1 | |
| 12 | 1993 | 6 | |
| 13 | Transient cytogenetic relapse in a Ph1-positive chronic myelogenous leukemia patient previously treated with alpha-interferon. | 1992 | 1 |
| 14 | 1991 | 4 | |
| 15 | 1991 | 6 | |
| 16 | 1990 | 5 | |
| 17 | 1990 | 4 | |
| 18 | 1990 | 12 | |
| 19 | 1989 | 36 | |
| 20 | 1988 | 7 |
About Simonetta Kerim
Simonetta Kerim is a scholar working on Hematology, Genetics, Oncology, Rheumatology and Pathology and Forensic Medicine, having authored 34 papers that have together received 521 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (8 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), Chronic Lymphocytic Leukemia Research (6 papers), Eosinophilic Disorders and Syndromes (5 papers), Lymphoma Diagnosis and Treatment (5 papers), Viral-associated cancers and disorders (4 papers) and Glycosylation and Glycoproteins Research (3 papers). The work is most often cited by research in Hematology (232 citations), Genetics (121 citations), Otorhinolaryngology (31 citations), Oncology (137 citations) and Pathology and Forensic Medicine (77 citations). Simonetta Kerim has collaborated with scholars based in Italy, Belgium and Belarus. Frequent co-authors include Guido Valente, Giorgio Palestro, Ciro Isidoro, Giuseppina Nicotra, Antonio Cuneo, Elisabeth Vandenberghe, Paola Dal Cin, J Rodhain, André Bosly and Angeline Van Orshoven. Their work appears in journals such as British Journal of Haematology, Blood, Cancer, Oncology Reports and Leukemia Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.